ExpreS2ion to participate in upcoming events
Hørsholm, Denmark, 3 November 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the Conference on Vaccines R&D (6-8 November), BIO-EUROPE (6-8 November) and the Vaccines Summit (13-15 November).
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.
6-8 November 2023 | Conference on Vaccines Research & Development
Baltimore, Maryland, USA (Virtual)
Dr. Farshad Guirakhoo, Chief Scientific Officer, is invited to present “Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancers.” He will present virtually on 8 November 2023 from 13:40 to 14:00 EST. The full list of speakers and more information about the event can be found on the event website.
6-8 November 2023 | BIO-EUROPE
Munich, Germany (In-person)
Meet CEO Bent Frandsen at the industry’s largest gathering of biopharma professionals in Europe. More information and registration are available at BIO-Europe’s website.
13-15 November 2023 | Vaccines Summit
Boston, MA (In-person)
CSO Dr. Farshad Guirakhoo is invited to present “Preclinical proof-of-concept studies of a novel human HER-2 virus-like particle as a vaccine candidate for human breast cancers.” He will chair the session on Cancer Vaccines & Immunotherapy, including his own presentation, on 15 November 2023 from 11:00 to 12:00 EST. The full list of speakers and more information about the event can be found on the event website.
To pre-arrange meetings at these events, please email ExpreS2ion at info@expres2ionbio.com.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.